NCT00548834View on ClinicalTrials.gov

Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Rheumatoid Arthritis
Interventions
DRUG

CDP870

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00548834 - Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter